| Therapeutic drug monitoring of amikacin in septic patients W Duszynska, FS Taccone, M Hurkacz, B Kowalska-Krochmal, ... Critical Care 17, 1-10, 2013 | 91 | 2013 |
| Venlafaxine pharmacogenetics: a comprehensive review J Suwała, M Machowska, A Wiela-Hojeńska Pharmacogenomics 20 (11), 829-845, 2019 | 44 | 2019 |
| Pseudoephedrine—benefits and risks K Głowacka, A Wiela-Hojeńska International Journal of Molecular Sciences 22 (10), 5146, 2021 | 40 | 2021 |
| Nephrotoxicity of herbal products in Europe—a review of an underestimated problem K Kiliś-Pstrusińska, A Wiela-Hojeńska International Journal of Molecular Sciences 22 (8), 4132, 2021 | 39 | 2021 |
| Evaluation of the toxicity of anticancer chemotherapy in patients with colon cancer A Wiela-Hojeńska, T Kowalska, E Filipczyk-Cisarż, Ł Łapiński, ... Advances in Clinical and Experimental Medicine 24 (1), 103-111, 2015 | 35 | 2015 |
| Pharmacokinetics of treosulfan and its active monoepoxide in pediatric patients after intravenous infusion of high-dose treosulfan prior to HSCT F Główka, A Kasprzyk, M Romański, T Wróbel, J Wachowiak, D Szpecht, ... European Journal of Pharmaceutical Sciences 68, 87-93, 2015 | 34 | 2015 |
| CYP2C19 polymorphism in relation to the pharmacotherapy optimization of commonly used drugs B Sienkiewicz-Oleszkiewicz, A Wiela-Hojeńska Die Pharmazie-An International Journal of Pharmaceutical Sciences 73 (11 …, 2018 | 33 | 2018 |
| Antibiotics and the nervous system—which Face of antibiotic therapy is real, dr. Jekyll (neurotoxicity) or mr. Hyde (neuroprotection)? M Hurkacz, L Dobrek, A Wiela-Hojeńska Molecules 26 (24), 7456, 2021 | 29 | 2021 |
| Niepożądane działania leków–rodzaje, podział, przyczyny i skutki ekonomiczne A Wiela-Hojeńska, Ł Łapiński Bezpieczeństwo farmakoterapii 4 (66), 275-288, 2010 | 20 | 2010 |
| Optimization of lidocaine application in tumescent local anesthesia K Głowacka, K Orzechowska-Juzwenko, A Bieniek, A Wiela-Hojeńska, ... Pharmacological Reports 61 (4), 641-653, 2009 | 20 | 2009 |
| The impact of liposomes on transdermal permeation of naproxen--in vitro studies. D Szura, Ł Ozimek, M Przybyło, K Karłowicz-Bodalska, ... Acta poloniae pharmaceutica 71 (1), 145-151, 2014 | 19 | 2014 |
| The importance of the polymorphisms of the ABCB1 gene in disease susceptibility, behavior and response to treatment in inflammatory bowel disease: A literature review PW Petryszyn, A Wiela-Hojeńska Adv Clin Exp Med 27 (10), 1459-63, 2018 | 15 | 2018 |
| CYP2D6 basic genotyping as a potential tool to improve the antiemetic efficacy of ondansetron in prophylaxis of postoperative nausea and vomiting PA Niewiński, R Wojciechowski, M Śliwiński, ME Hurkacz, K Głowacka, ... Advances in Clinical and Experimental Medicine 27 (11), 1499-1503, 2018 | 14 | 2018 |
| Comparison of clinical pharmacology of voriconazole and posaconazole BM Sienkiewicz, Ł Łapiński, A Wiela-Hojeńska Contemporary Oncology/Współczesna Onkologia 20 (5), 365-373, 2016 | 12 | 2016 |
| Safety of oral nifuroxazide–analysis of data from a spontaneous reporting system K Karlowicz-Bodalska, K Głowacka, K Boszkiewicz, S Han, ... Acta Poloniae Pharmaceutica-Drug Research 76 (4), 745-751, 2019 | 11 | 2019 |
| Influence of CYP2C19 genotypes on the occurrence of adverse drug reactions of voriconazole among hematological patients after Allo-HSCT B Sienkiewicz, D Urbaniak-Kujda, J Dybko, A Dryś, M Hurkacz, T Wróbel, ... Pathology & Oncology Research 24, 541-545, 2018 | 10 | 2018 |
| Renal tubular dysfunction in patients with rheumatoid arthritis starting with low dose of methotrexate P Wiland, A Wiela-Hojeńska, J Swierkot, M Hurkacz, ... Polskie Archiwum Medycyny Wewnetrznej 110 (2), 855-862, 2003 | 10 | 2003 |
| Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes K Urbańczyk, S Guntschnig, V Antoniadis, S Falamic, T Kovacevic, ... Frontiers in pharmacology 14, 1244151, 2023 | 9 | 2023 |
| C3435T Polymorphism of the ABCB1 Gene in Polish Patients with Inflammatory Bowel Disease: A Case–Control and Meta-Analysis Study P Petryszyn, R Dudkowiak, A Gruca, E Jaźwińska-Tarnawska, ... Genes 12 (9), 1419, 2021 | 8 | 2021 |
| Międzynarodowe i krajowe systemy monitorowania niepożądanych działań leków–ich rozpoznawanie i zgłaszanie A Wiela-Hojeńska, E Jaźwińska-Tarnawska Farm Pol 65 (10), 725-732, 2009 | 8 | 2009 |
